Clinical Research Directory
Browse clinical research sites, groups, and studies.
Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding
Sponsor: Donald Arnold
Summary
This pilot study aims to gather preliminary evidence on how different hemoglobin levels impact blood biomarkers related to bleeding. The feasibility of conducting a future larger clinical trial will also be assessed. Red blood cell transfusions are part of the standard of care for patients with leukemia. This study evaluates two transfusion strategies: one that maintains hemoglobin levels above the standard-of-care threshold, reflecting current routine practice; and another that maintains hemoglobin levels above 110 g/L, which is closer to the normal hemoglobin range. The normal hemoglobin range is 120-160 g/L for females and 140-180 g/L for males. Raising hemoglobin levels closer to normal values may reduce bleeding risk.
Official title: Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding (BAIT): A Pilot Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-04-11
Completion Date
2026-11-01
Last Updated
2025-04-27
Healthy Volunteers
No
Interventions
RBC transfusion strategy
RBC transfusion strategy to maintain a hemoglobin level of at least 110 g/L.
Locations (1)
Juravinski Hospital
Hamilton, Ontario, Canada